Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0000903423-19-000277 0001103804 XXXXXXXX LIVE 6 Common Stock, par value $0.001 per share 01/31/2025 false 0001743881 10806X102 BridgeBio Pharma, Inc. 3160 Porter Drive Suite 250 Palo Alto CA 94304 Matthew Bloom (212) 672-7059 General Counsel 600 Washington Boulevard, Floor 11 Stamford CT 06901 0001103804 VIKING GLOBAL INVESTORS LP b OO DE 0 22055375 0 22055375 22055375 N 11.7 PN All share percentage calculations in this Amendment No. 6 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024. 0001132625 VIKING GLOBAL PERFORMANCE LLC b OO DE 0 487901 0 487901 487901 N 0.3 OO 0001759530 Viking Global Equities Master Ltd. b OO E9 0 487901 0 487901 487901 N 0.3 CO 0001621607 Viking Long Fund GP LLC b OO DE 0 194184 0 194184 194184 N 0.1 OO 0001621596 Viking Long Fund Master Ltd. b OO E9 0 194184 0 194184 194184 N 0.1 CO 0001886738 Viking Global Opportunities Parent GP LLC b OO DE 0 21373290 0 21373290 21373290 N 11.3 OO 0001629476 Viking Global Opportunities GP LLC b OO DE 0 21373290 0 21373290 21373290 N 11.3 OO 0001629472 Viking Global Opportunities Portfolio GP LLC b OO DE 0 21373290 0 21373290 21373290 N 11.3 OO 0001629482 Viking Global Opportunities Illiquid Investments Sub-Master LP b OO E9 0 21373290 0 21373290 21373290 N 11.3 PN 0001133006 HALVORSEN OLE ANDREAS b OO Q8 0 22055375 0 22055375 22055375 N 11.7 IN 0001621842 Ott David C. b OO X1 0 22055375 0 22055375 22055375 N 11.7 IN 0001711393 Shabet Rose Sharon b OO X1 0 22055375 0 22055375 22055375 N 11.7 IN Common Stock, par value $0.001 per share BridgeBio Pharma, Inc. 3160 Porter Drive Suite 250 Palo Alto CA 94304 Pursuant to Rule 13d-2 under the Securities Exchange Act of 1934, as amended, this Amendment No. 6 to the Schedule 13D ("Amendment No. 6") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023, Amendment No. 3 filed with the Commission on August 20, 2024 Amendment No. 4 filed with the Commission on November 6, 2024 and Amendment No. 5 filed with the Commission on January 31, 2025 (collectively, the "Schedule 13D") relating to the Common Stock, par value $0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. This Amendment No. 6 is being filed solely to change the title of the person authorized to receive notices and communications on the first page of the Schedule 13D. VIKING GLOBAL INVESTORS LP /s/ Scott M. Hendler Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3) 03/12/2025 VIKING GLOBAL PERFORMANCE LLC /s/ Scott M. Hendler Scott M. Hendler on behalf of VIKING GLOBAL PERFORMANCE LLC (1)(2)(3) 03/12/2025 Viking Global Equities Master Ltd. /s/ Scott M. Hendler Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3) 03/12/2025 Viking Long Fund GP LLC /s/ Scott M. Hendler Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3) 03/12/2025 Viking Long Fund Master Ltd. /s/ Scott M. Hendler Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3) 03/12/2025 Viking Global Opportunities Parent GP LLC /s/ Scott M. Hendler Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3) 03/12/2025 Viking Global Opportunities GP LLC /s/ Scott M. Hendler Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3) 03/12/2025 Viking Global Opportunities Portfolio GP LLC /s/ Scott M. Hendler Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3) 03/12/2025 Viking Global Opportunities Illiquid Investments Sub-Master LP /s/ Scott M. Hendler Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3) 03/12/2025 HALVORSEN OLE ANDREAS /s/ Scott M. Hendler Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1) 03/12/2025 Ott David C. /s/ Scott M. Hendler Scott M. Hendler on behalf of Ott David C. (2) 03/12/2025 Shabet Rose Sharon /s/ Scott M. Hendler Scott M. Hendler on behalf of Shabet Rose Sharon (3) 03/12/2025 (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).